NCT02125084View on ClinicalTrials.gov

Enzalutamide Plus Everolimus in Men With Metastatic Castrate-Resistant Prostate Cancer

PHASE1CompletedINTERVENTIONAL

Enrollment

38

Participants

Timeline

Start Date

October 31, 2014

Primary Completion Date

May 3, 2021

Study Completion Date

May 3, 2021

Conditions

Prostate Cancer

Interventions

DRUG

Everolimus

DRUG

Enzalutamide

Trial Locations (5)

33705

Florida Cancer Center, St. Petersburg

33916

Florida Cancer Specialists, Fort Myers

37203

Tennessee Oncology PLLC, Nashville

37404

Tennessee Oncology, Chattanooga

45242

Oncology Hematology Care Inc., Cincinnati

Sponsors

Collaborators (1)

Novartis Pharmaceuticals

All Listed Sponsors

collaborator

Novartis Pharmaceuticals

INDUSTRY

lead

SCRI Development Innovations, LLC

OTHER